Invest in Fisher Wallace
Class B Common Stock For Sale
- 200% Bonus Shares until Oct 6
Example: Buy 100 Shares → Receive 300 Shares - Raise Capped at $900,024
|
Share Price $11.34 |
Company Updates
- On September 2, 2025, Fisher Wallace executed a Cooperative Research and Development Agreement (CRADA) with the U.S. Department of Veterans Affairs
- The electrical field model recently completed by researchers at Massachusetts General Hospital and Harvard Medical School demonstrates that OAK engages the Anterior Cingulate Cortex, Thalamus, Amygdala, Insula, Hippocampus, and other brain structures integral to mood, sleep and cognition
- Anticipated date of FDA Clearance / 510(k) for the treatment of anxiety: Q2 2026
- Anticipated completion date of OAK prototypes: Q2 2026
Scale of Problem
As many as 140 million Americans and 2.5 billion people globally have clinically significant symptoms of anxiety, depression and/or insomnia.
Scientific Evidence
More than any other wearable brain stimulation device
COMPLETED for FDA Clearance:
- 8-Week Real World Anxiety Study
Pending Publication
COMPLETED to Validate Pivotal Trials for Depression and Insomnia:
- 4-Week, Randomized, Controlled Depression Study
Published in The Journal of Clinical Psychiatry, 2024 - 4-Week, Randomized, Controlled Insomnia Study
Exploratory Study
ADDITIONAL COMPLETED Pilot Studies: Bipolar II Depression, PTSD, Parkinson’s Disease, Substance Use Disorder
Better Tech For Veterans
Our upcoming feasibility study at the U.S. Department of Veterans Affairs, will evaluate at-home use of our technology as a scalable, safe, and rapid-acting adjunct to traditional mental health care–to expand access at a time when patient need continues to outpace the availability of services.
Better Tech for Gen Z and Gen Alpha
OAK was designed and engineered by the teams behind Beats and Nest to appeal to Gen Alpha and Gen Z –the generations that exhibit the highest prevalence of depression and anxiety.
Product-Market-Fit
Under temporary FDA clearance, Fisher Wallace commercialized its proof-of-concept Version 1.0 device and began making mental health history:
- 100K units sold
- 14K prescribers
- $40M in revenue
- Medicaid reimbursement (MaineCare)
We expect as many as 60K Version 1.0 customers to upgrade to OAK upon its commercial release.
World-Class Advisors
Dr. Maurizio Fava
Psychiatrist-in-Chief, Massachusetts General Hospital
Dr. David Shulkin
Fmr US Secretary of Veterans Affairs
Fmr CEO of Beth Israel Medical Center
Board Member, Maclean Health
Relentless Co-Founders
Kelly Roman
Co-Founder and CEO
(Will provide text for this)
Charles “Chip” Fisher
Co-Founder and Chairman
(Will provide text for this)
Citations
United States
- SAMHSA. 2021 NSDUH Annual Report. 2022.
- NIMH. Major Depression. 2022.
- NIMH. Any Anxiety Disorder. 2022.
- CDC. Sleep Difficulties Among Adults: United States, 2020. NCHS Data Brief No. 436. 2022.
- American Academy of Sleep Medicine. 12% of Americans diagnosed with chronic insomnia. June 2024.
- Gooch CL, Pracht E, Borenstein AR. Burden of neurological disease in the U.S. Ann Neurol. 2017;81(4):479–484.
- GBD 2017 U.S. Neurological Disorders Collaborators. Burden of neurological disorders across the U.S., 1990–2017. JAMA Neurol. 2021;78(2):165–176.
Global
- WHO. Mental Disorders Fact Sheet (2019 data). Updated 2023.
- WHO. Depression Fact Sheet (2019 data). Updated 2024.
- GBD 2021 Nervous System Disorders Collaborators. Global burden of disorders affecting the nervous system, 1990–2021. Lancet Neurol. 2024;23(4):344–381.
- Morin CM, Jarrin DC. Epidemiology of Insomnia. Sleep Med Clin. 2022;17(2):173–191.
- Caponnetto V, et al. Comorbidities of primary headache disorders. J Headache Pain. 2021;22(1):71.
- Hackett ML, Pickles K. Depression after stroke: meta-analysis. Int J Stroke. 2014;9(8):1017–25.
- Broen MPG, et al. Prevalence of anxiety in Parkinson’s disease. Mov Disord. 2016;31(8):1125–33.
- Cong S, et al. Depression in Parkinson’s disease. J Affect Disord. 2022;301:342–358.
Frequently asked questions
1. Why invest in startups?
Regulation CF allows investors to invest in startups and early-growth companies. This is different from helping a company raise money on Kickstarter; with Regulation CF Offerings, you aren’t buying products or merchandise – you are buying a piece of a company and helping it grow.
2. How much can I invest?
Accredited investors can invest as much as they want. But if you are NOT an accredited investor, your investment limit depends on either your annual income or net worth, whichever is greater. If the number is less than $124,000, you can only invest 5% of it. If both are greater than $124,000 then your investment limit is 10%.
3. How do I calculate my net worth?
To calculate your net worth, just add up all of your assets and subtract all of your liabilities (excluding the value of the person’s primary residence). The resulting sum is your net worth.
4. What are the tax implications of an equity crowdfunding investment?
We cannot give tax advice, and we encourage you to talk with your accountant or tax advisor before making an investment.
5. Who can invest in a Regulation CF Offering?
Individuals over 18 years of age can invest.
6. What do I need to know about early-stage investing? Are these investments risky?
There will always be some risk involved when investing in a startup or small business. And the earlier you get in the more risk that is usually present. If a young company goes out of business, your ownership interest could lose all value. You may have limited voting power to direct the company due to dilution over time. You may also have to wait about five to seven years (if ever) for an exit via acquisition, IPO, etc. Because early-stage companies are still in the process of perfecting their products, services, and business model, nothing is guaranteed. That’s why startups should only be part of a more balanced, overall investment portfolio.
7. Can I sell my Notes?
The Convertible Notes (the “Notes”) of Fisher Wallace Laboratories, Inc. (the “Company”) are not publicly-traded. As a result, the Notes cannot be easily traded or sold. Notes are debt securities that are designed to raise capital from investors, who in turn receive the promise of regular interest payments and the return of the principal amount (the original investment) at a specified future date, known as the maturity date. The Company is offering the Notes with a 10% annual interest rate that is to be paid out in monthly quarterly beginning on June 12, 2026 with a maturity date of March 12, 2027.
8. Can I sell my shares?
The Common Stock (the “Shares”) of Fisher Wallace Laboratories (the “Company”) are not publicly-traded. As a result, the shares cannot be easily traded or sold. As an investor in a private company, you typically look to receive a return on your investment under the following scenarios: The Company gets acquired by another company. The Company goes public (makes an initial public offering). In those instances, you receive your pro-rata share of the distributions that occur, in the case of acquisition, or you can sell your shares on an exchange. These are both considered long-term exits, taking approximately 5-10 years (and often longer) to see the possibility for an exit. It can sometimes take years to build companies. Sometimes there will not be any return, as a result of business failure. Shares sold via Regulation Crowdfunding offerings have a one-year lockup period before those shares can be sold under certain conditions.
9. Exceptions to limitations on selling shares during the one-year lockup period:
In the event of death, divorce, or similar circumstance, shares can be transferred to:
• The company that issued the securities
• An accredited investor
• A family member (child, stepchild, grandchild, parent, stepparent, grandparent, spouse or equivalent, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships)
10. What happens if a company does not reach their funding target?
If a company does not reach their minimum funding target, all funds will be returned to the investors after the close of the offering.
11. How can I learn more about a company’s offering?
All available disclosure information can be found on the offering pages for our Regulation Crowdfunding offering.
12. What if I change my mind about investing?
You can cancel your investment at any time, for any reason, until 48 hours prior to a closing occurring. If you’ve already funded your investment and your funds are in escrow, your funds will be promptly refunded to you upon cancellation. To submit a request to cancel your investment please email: info@dealmakersecurities.com
13. How do I keep up with how the company is doing?
At a minimum, the company will be filing with the SEC and posting on it’s website an annual report, along with certified financial statements. Those should be available 120 days after the fiscal year end. If the company meets a reporting exception, or eventually has to file more reported information to the SEC, the reporting described above may end. If these reports end, you may not continually have current financial information about the company.
14. What relationship does the company have with DealMaker Securities?
Once an offering ends, the company may continue its relationship with DealMaker Securities for additional offerings in the future. DealMaker Securities’ affiliates may also provide ongoing services to the company. There is no guarantee any services will continue after the offering ends.